Simplify Logo

Full-Time

Head – Clinical Quality

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Hardware
Biotechnology

Senior, Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Management
Quality Assurance (QA)
Requirements
  • Bachelor's degree in the Life Sciences with 10+ years in pharmaceutical or biotech drug development. Advanced degree preferred. Minimum 10 years of experience in Clinical QA.
  • Demonstrated experience working with Clinical Trial teams
  • Extensive experience with global clinical trial conduct, knowledge and understanding of ICH E6 GCP Guidelines, FDA Regulations and EU Requirements
  • Previous experience supporting Regulatory Authority Inspections
  • Excellent leadership and interpersonal skills with an ability to effectively work and problem solve within a multidisciplinary team.
Responsibilities
  • Participate and proactively provide GXP QA support and guidance in the implementation of GXP compliant procedures and operations to ensure a robust quality management system for the conduct and maintenance of clinical studies
  • Develop and implement process improvements to internal programs as indicated by issue management, audit observations, new regulations, guidance documents, and industry standards. Assist cross-functional teams as necessary with the development, review and implementation of SOPs
  • Lead Inspection Preparation and support Inspection Readiness activities. Drives strategies for Preparation, Support and Follow-up activities for Inspection Readiness
  • Manage the resolution of compliance issues (e.g. CAPAs) identified at clinical vendors and clinical sites and provide assessment of the impact of any deficiencies. Assist teams in the development of CAPA plans and investigations in response to quality issues, audits, and inspections. Lead/chair the clinical portion of Quality Management Review
  • Lead Quality Event Management activities related to the investigation, root cause analysis and development of corrective action/ preventive action plans within Clinical R&D.
  • Collaborate with stakeholders in conducting ongoing risk assessments of clinical study activity to identify priority studies, compliance metrics for tracking, high-risk service providers, and key Clinical QA activities (i.e., protocol review, service provider risk mitigations, inspection readiness)
  • Maintain high level of expertise in global GCP regulations and internal policies and procedures that impact clinical study conduct. Conduct impact assessments of new regulations, guidances, and potential trends that may impact Clinical R&D.
  • Reviews and analyzes key Performance Indicator data and trends within organization as well as external assessments.
  • Analyzes risk and proposes remedial, corrective and /or preventive actions
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$548.9M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

8%

2 year growth

61%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.